GlobeNewswire by notified

Cority Launches Vaccination Management Solution to Help Organizations Comply with Widespread COVID-19 Vaccine Mandates

Share

New rapidly deployable solution simplifies the collection, tracking, and reporting of employee vaccination status to ensure compliance with vaccine mandate policies and support a safer workplace

Toronto, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cority, the leading global enterprise Environmental, Health, and Safety (EHS) software provider, today announced the immediate availability of its new Vaccination Management solution. Designed by certified occupational health and safety experts, the new solution helps organizations streamline and simplify workplace vaccination status management at scale, enabling the collection, validation, and reporting of employee vaccination status and COVID-19 test results from a single, secure location.

Following the surge in government-imposed vaccine mandates, including the Biden administration’s COVID-19 Action Plan announcement, which imposes wide-scale workforce vaccination and COVID-19 testing requirements, organizations are under increased pressure to implement vaccination policies to reduce the risk of workplace transmission and protect the health and safety of employees. As more organizations adopt vaccine mandates, they will need to rapidly operationalize their vaccination policies, including accurately tracking workforce vaccination status, validating test results for unvaccinated workers, and meeting regulatory reporting obligations.

“Most organizations haven’t been in this situation before and simply lack the resources to support a vaccination mandate policy,” said Michael Couture, Chief Product Officer, Cority. “Our goal is to make it as easy as possible for employers of all sizes to confidently collect and track workforce vaccination status at scale, successfully demonstrate compliance, and create a safer work environment for employees.” 

Cority has been providing Occupational Health solutions, including tools to manage employee immunizations, for over 30 years. The new Vaccination Management solution is the latest addition to Cority’s industry-leading Health Cloud and part of a series of packaged solutions designed to support organizations throughout each phase of the pandemic. Over 200 global organizations are currently using Cority’s COVID-19 solutions to operationalize pandemic response plans and maintain a healthy workforce, including its award-winning COVID-19 Return to Work and Productivity Solution

Key features of Cority’s new Vaccination Management Solution include:

  • Mobile self-declaration – enables employees to easily complete vaccination disclosures and securely submit proof of vaccination status or COVID-19 test results from any device

  • Vaccination status surveillance – automatically enrolls unvaccinated or partially vaccinated employees into a surveillance group and sends reminder notifications to submit weekly test results

  • Rapid vaccination administration – optimizes on-site vaccination clinic administration with built-in barcode scanning functionality to simplify vaccine inventory management and streamline charting practices

  • Business intelligence and analytics – pre-configured dashboards and reports provide insight into workforce vaccination status trends and simplifies monitoring and reporting of vaccination mandate program key performance metrics


To learn more about how Cority’s Vaccination Management solution can help your organization optimize its employee vaccine status tracking, recordkeeping, and compliance, watch this 90-second video, Making Vaccination Management Easy

About Cority
Cority is the global enterprise EHS software provider creating industry-leading technology to empower those who transform the way the world works.  For over 35 years, Cority has been powered by the spirit of innovation, deep domain expertise, and a commitment to integrity that enables higher levels of operational and sustainable performance with the most comprehensive, human-centered, and secure SaaS platform to help workers and businesses thrive in 100 countries around the world. The company enjoys the industry’s highest levels of client satisfaction and has received many awards for its strong employee culture and outstanding business performance. To learn more, visit www.cority.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10

Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release

The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and

SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release

Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie

HiddenA line styled icon from Orion Icon Library.Eye